HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino reiterates a Buy rating on Eledon Pharma (NASDAQ:ELDN) and maintains a $13 price target.
March 22, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Eledon Pharma with a $13 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $13 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the potential of Eledon Pharma. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100